Dividend Flows Coverage: Zoetis Inc. (NYSE:ZTS) advises investors to expect $0.10 dividends on Dec 1, 2016.

Dividend Flows Coverage: Zoetis Inc. (NYSE:ZTS) advises investors to expect $0.10 dividends on Dec 1, 2016.

Zoetis Inc. (NYSE:ZTS) is expected to pay $0.10 on Dec 1, 2016. The indicated annual dividend is $0.38. Shareholders owning the stock before Nov 1, 2016 will be eligible to receive the payout. Based on Zoetis Inc.’s current price of $48.56, the dividend is 0.20%. This dividend’s record date is Nov 3, 2016 and the announcement date is Oct 6, 2016. The stock decreased 0.43% or $0.21 on October 28, hitting $48.56. Zoetis Inc (NYSE:ZTS) has risen 12.62% since March 29, 2016 and is uptrending. It has outperformed by 9.14% the S&P500.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The company has a market cap of $23.94 billion. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish , and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. It has a 37.94 P/E ratio. It operates through two divisions: the United States and International.

Insitutional Activity: The institutional sentiment increased to 1.08 in 2016 Q2. Its up 0.15, from 0.93 in 2016Q1. The ratio improved, as 48 funds sold all Zoetis Inc shares owned while 212 reduced positions. 72 funds bought stakes while 210 increased positions. They now own 451.82 million shares or 1.32% less from 457.84 million shares in 2016Q1.
Fmr Limited Liability Com has invested 0% of its portfolio in Zoetis Inc (NYSE:ZTS). Evercore Wealth Mngmt Limited Liability Company holds 0.01% of its portfolio in Zoetis Inc (NYSE:ZTS) for 3,402 shares. National Bank & Trust Of New York Mellon Corporation has invested 0.06% of its portfolio in Zoetis Inc (NYSE:ZTS). Cleararc Capital Inc holds 11,106 shares or 0.1% of its portfolio. Blackrock Inc holds 0.08% or 1.08M shares in its portfolio. Catalyst Advsrs Limited Liability Company holds 0% or 67 shares in its portfolio. Legal & General Group Inc Public Ltd Limited Liability Company last reported 2.11M shares in the company. Caisse De Depot Et Placement Du Quebec holds 0.01% or 83,237 shares in its portfolio. Veritable Limited Partnership owns 12,058 shares or 0.01% of their US portfolio. Nomura Asset Mngmt Company holds 0.05% of its portfolio in Zoetis Inc (NYSE:ZTS) for 52,920 shares. Raymond James Trust Na last reported 5,909 shares in the company. Point72 Asset Mgmt Ltd Partnership last reported 1.42% of its portfolio in the stock. Continental Advsr Ltd Liability Com accumulated 36,700 shares or 0.54% of the stock. Thompson Siegel And Walmsley Ltd Co, a Virginia-based fund reported 18,150 shares. Tokio Marine Asset Mngmt holds 0.08% or 15,448 shares in its portfolio.

Insider Transactions: Since May 9, 2016, the stock had 1 insider purchase, and 3 insider sales for $786.61 million net activity. 13,870 Zoetis Inc (NYSE:ZTS) shares with value of $710,838 were sold by Fenton Andrew. MCCALLISTER MICHAEL B had bought 2,000 shares worth $102,680 on Tuesday, September 6. Another trade for 16.85M shares valued at $784.37M was sold by Pershing Square Capital Management – L.P.. Chen Heidi C. sold $1.64M worth of stock.

Zoetis Inc (NYSE:ZTS) Ratings Coverage

Out of 11 analysts covering Zoetis Inc (NYSE:ZTS), 8 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 73% are positive. $58 is the highest target while $48 is the lowest. The $53.50 average target is 10.17% above today’s ($48.56) stock price. Zoetis Inc has been the topic of 20 analyst reports since July 24, 2015 according to StockzIntelligence Inc. Citigroup maintained the stock with “Neutral” rating in Thursday, August 4 report. The firm has “Buy” rating given on Tuesday, March 15 by Jefferies. On Friday, May 6 the stock rating was downgraded by Goldman Sachs to “Sell”. The stock of Zoetis Inc (NYSE:ZTS) earned “Equal-Weight” rating by Barclays Capital on Thursday, August 4. The stock has “Outperform” rating given by Credit Suisse on Thursday, February 4. As per Thursday, September 29, the company rating was initiated by Bank of America. Zacks upgraded the shares of ZTS in a report on Thursday, September 17 to “Buy” rating. The rating was upgraded by William Blair to “Outperform” on Thursday, August 6. On Friday, September 11 the stock rating was upgraded by BMO Capital Markets to “Outperform”. Jefferies maintained the stock with “Buy” rating in Tuesday, June 14 report.

More recent Zoetis Inc (NYSE:ZTS) news were published by: Forbes.com which released: “December 16th Options Now Available For Zoetis (ZTS)” on October 24, 2016. Also Forbes.com published the news titled: “Ex-Dividend Reminder: Ambev, KB Home and Zoetis” on October 28, 2016. Zacks.com‘s news article titled: “Zoetis (ZTS) Q3 Earnings: Stock Likely to Beat Estimates” with publication date: October 27, 2016 was also an interesting one.

ZTS Company Profile

Zoetis Inc., incorporated on July 25, 2012, is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Firm has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Firm operates through two divisions: the United States and International. Within each of these divisions, the Company offers a diversified product portfolio for both livestock and companion animal customers. In addition, its Client Supply Services (CSS) organization provides contract manufacturing services to third parties.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment